BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 24248532)

  • 1. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
    Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
    Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
    Wang X; Chen JX; Liu YH; You C; Mao Q
    Neurol Sci; 2013 Aug; 34(8):1421-8. PubMed ID: 23224642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results.
    Li S; Jiang T; Li G; Wang Z
    Neurol Res; 2008 Jul; 30(6):567-70. PubMed ID: 18647495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT gene promoter methylation in pediatric glioblastomas.
    Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
    Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    Kurdi M; Butt NS; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Dallol A; Mohamed F; Bari MO; Samkari A; Lary AI; Alkhayyat S
    J Neurooncol; 2021 May; 152(3):541-549. PubMed ID: 33661424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of molecular biomarkers in glioblastoma.
    Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
    Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
    Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
    Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.